<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516490</url>
  </required_header>
  <id_info>
    <org_study_id>AH-47/07</org_study_id>
    <nct_id>NCT00516490</nct_id>
  </id_info>
  <brief_title>GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>V.K.V. American Hospital, Istanbul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>V.K.V. American Hospital, Istanbul</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles
      was reported to increase pregnancy and birth rates. This study was done to evaluate the
      reproducibility of previous findings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GnRH agonist administration in the luteal phase was reported to beneficially affect clinical
      outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single
      dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles
      stimulated with the long GnRH agonist protocol. Women undergoing embryo transfer following
      controlled ovarian hyperstimulation with a long GnRH agonist protocol were included. In
      addition to routine luteal phase support with progesterone women were randomized to receive a
      single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was
      the primary outcome measure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate beyond 20 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo implantation rate</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">570</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GnRH agonist administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile saline injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin acetate</intervention_name>
    <description>Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Decapeptyl Ferring GmBH Kiel Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Na Cl %0.9</intervention_name>
    <description>0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Isotonik NaCl %0.09 Eczacibasi-Baxter Istanbul Turkey</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing embryo transfer following controlled ovarian hyperstimulation with a
             long GnRH agonist protocol, oocyte pick-up and ICSI.

          -  Embryo transfer performed on day 3.

        Exclusion Criteria:

          -  Participation in another trial that was being conducted in our unit at the same time.

          -  Preimplantation genetic screening cycles.

          -  Day 5 embryo transfers.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baris Ata, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Assisted Reproduction Unit of the American Hospital of Istanbul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bulent Urman, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Assisted Reproduction Unit of the American Hospital of Istanbul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amerikan Hastanesi TÃ¼p Bebek Merkezi</name>
      <address>
        <city>Istanbul</city>
        <zip>34365</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006 Oct;21(10):2572-9. Epub 2006 Aug 22.</citation>
    <PMID>16926261</PMID>
  </reference>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>August 14, 2007</last_update_submitted>
  <last_update_submitted_qc>August 14, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2007</last_update_posted>
  <keyword>GnRH agonist</keyword>
  <keyword>IVF/ICSI outcome</keyword>
  <keyword>luteal phase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

